ATE189814T1 - Hydroxypyridin-derivate, ihre herstellung und ihre pharmazeutische verwendung - Google Patents

Hydroxypyridin-derivate, ihre herstellung und ihre pharmazeutische verwendung

Info

Publication number
ATE189814T1
ATE189814T1 AT97106079T AT97106079T ATE189814T1 AT E189814 T1 ATE189814 T1 AT E189814T1 AT 97106079 T AT97106079 T AT 97106079T AT 97106079 T AT97106079 T AT 97106079T AT E189814 T1 ATE189814 T1 AT E189814T1
Authority
AT
Austria
Prior art keywords
group
substituted
alkyl group
halogen
hydrogen atom
Prior art date
Application number
AT97106079T
Other languages
English (en)
Inventor
Mitsuru Shiraishi
Tsuyoshi Maekawa
Toshifumi Watanabe
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ATE189814T1 publication Critical patent/ATE189814T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
AT97106079T 1996-04-15 1997-04-14 Hydroxypyridin-derivate, ihre herstellung und ihre pharmazeutische verwendung ATE189814T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9290496 1996-04-15

Publications (1)

Publication Number Publication Date
ATE189814T1 true ATE189814T1 (de) 2000-03-15

Family

ID=14067477

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97106079T ATE189814T1 (de) 1996-04-15 1997-04-14 Hydroxypyridin-derivate, ihre herstellung und ihre pharmazeutische verwendung

Country Status (5)

Country Link
US (1) US5891895A (de)
EP (1) EP0802187B1 (de)
AT (1) ATE189814T1 (de)
CA (1) CA2202578A1 (de)
DE (1) DE69701298T2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080300281A1 (en) * 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US20080269265A1 (en) * 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
EP2298311B1 (de) * 1999-01-13 2012-05-09 Bayer HealthCare LLC Omega-carboxyarylsubstituierte-Diphenyl-Harnstoffe als p38-Kinasehemmer
EP1140840B1 (de) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
EP2305255B1 (de) * 2001-12-03 2012-08-22 Bayer HealthCare LLC Arylharnstoff-Verbindungen in Kombination mit anderen zytostatisch oder zytotoxisch wirksamen Stoffen zur Behandlungen menschlicher Krebserkrankungen
ATE529406T1 (de) 2002-02-11 2011-11-15 Bayer Healthcare Llc Aryl-harnstoffe als kinase inhibitoren
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
WO2003068223A1 (en) * 2002-02-11 2003-08-21 Bayer Corporation Aryl ureas with raf kinase and angiogenesis inhibiting activity
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
EP1636585B2 (de) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl-harnstoffe mit kinasehemmender wirkung
WO2005000835A1 (en) * 2003-06-26 2005-01-06 Novartis Ag Process for preparing intermediates useful to prepare certain antibacterial n-formyl hydroxylamines
PL1663978T3 (pl) * 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
US7838524B2 (en) * 2004-04-30 2010-11-23 Bayer Healthcare Llc Substituted pyrazolyl urea derivatives useful in the treatment of cancer
WO2006084031A1 (en) * 2005-02-01 2006-08-10 Icagen, Inc. Imines as ion channel modulators

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH350461A (de) * 1957-12-06 1960-11-30 Ciba Geigy Verwendung von Oxyketonen zum Schutze gegen ultraviolette Strahlung
JPS49119718A (de) * 1973-03-23 1974-11-15
CH609980A5 (en) * 1974-08-30 1979-03-30 Ciba Geigy Ag Process for the preparation of novel piperidine derivatives
US4297359A (en) * 1978-07-25 1981-10-27 Acf Chemiefarma Nv Anti-ulcer compositions containing certain pyridyl oxime ethers
US4798841A (en) * 1987-03-31 1989-01-17 Warner-Lambert Company Tetrahydropyridine oxime cholinergic agents and method of treatment
DK270488D0 (da) * 1988-05-18 1988-05-18 Novo Industri As Hidtil ukendte o-substituerede ketoximer
JP2765876B2 (ja) * 1988-10-24 1998-06-18 科研製薬株式会社 ピリジルケトオキシムエーテル誘導体
EP0388682A1 (de) * 1989-03-15 1990-09-26 Bayer Ag Substituierte Heteroarylphenylether, Verfahren zu ihrer Herstellung und ihre Verwendung als Insektizide
FR2644456B1 (fr) * 1989-03-17 1991-07-05 Rhone Poulenc Sante Nouveaux derives du 1h, 3h-pyrrolo(1,2-c)thiazolecarboxamide-7, leur preparation et les compositions pharmaceutiques qui les contiennent
JPH0499767A (ja) * 1990-08-20 1992-03-31 Nippon Bayeragrochem Kk 3―ベンゾイルピリジン0―ベンジルオキシム類の除草剤としての利用
DE69333894D1 (de) * 1992-04-22 2005-12-01 Ligand Pharm Inc Verbindungen mit Retinoid x rezeptorselektivität
TW266206B (de) * 1993-04-28 1995-12-21 Takeda Pharm Industry Co Ltd
JPH08175994A (ja) * 1994-10-27 1996-07-09 Takeda Chem Ind Ltd 脂質代謝改善剤

Also Published As

Publication number Publication date
EP0802187A1 (de) 1997-10-22
EP0802187B1 (de) 2000-02-16
DE69701298T2 (de) 2000-10-05
US5891895A (en) 1999-04-06
CA2202578A1 (en) 1997-10-15
DE69701298D1 (de) 2000-03-23

Similar Documents

Publication Publication Date Title
DE69701298D1 (de) Hydroxypyridin-Derivate, ihre Herstellung und ihre pharmazeutische Verwendung
EP1035123A4 (de) Neue heterozyklische verbindungen
DE69418704D1 (de) Anthranilsäure derivate
DE69814375D1 (de) Fungizide trifluoromethylalkylamino-triazolopyrimidine-derivate
ATE68180T1 (de) Morpholinoethylester von mycophenolsaeure und ihre derivate, ihre herstellung und verwendung in pharmazeutische zusammensetzungen.
LU91196I2 (fr) Picoxystrobin et ses dérivlés pharmaceutiquement acceptables(ACANTO).
DE3777735D1 (de) Imid-derivate, ihre herstellung und ihre verwendung.
ATE89556T1 (de) Naphthalenverbindungen und antiallergische und antiinflammatorische pharmazeutische mittel.
ATE199253T1 (de) Antidepressiv wirkende 3-halophenylpiperazinyl- propylderivate von substituierten triazolonen und triazoldionen
DE3767778D1 (de) Entzuendung verhindernde und allergie heilende mittel.
ATE92489T1 (de) Imid-derivate, ihre herstellung und verwendung.
ATE260252T1 (de) Thiocolchicin-derivate mit entzündungshemmender und muskelrelaxierender wirkung
FI844333L (fi) 11-substituerade 5h,11h-pyrrolo/2,1-c/ /1,4/benzoxazepiner, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
NZ221699A (en) Pyridazinone derivatives; pharmaceutical compositions and intermediates
DK0436348T3 (da) Pyridylcyklopropanderivater med fungicid aktivitet
ATE63541T1 (de) N-phenylethylaminoalkyl-benzamide als antiarrhythmische mittel.
TR200001941T1 (tr) TNF ve PDE-IV önleyici aktiviteye sahip heterosiklik bileşiklerin N-oksitleri.
FI941963A0 (fi) Pyridiinijohdannaiset, niiden valmistus ja käyttö
ATE205209T1 (de) Chinolincarbonsäurederivate und ihre salze
MX9202994A (es) Derivados de 2-aminoacetamida.
ATE218138T1 (de) N-substituierte azabicycloheptan-derivate, ihre herstellung und verwendung
DE69914563D1 (de) Azaindol derivate und ihre Verwendung als antithrombotische Wirkstoffe
ATE104270T1 (de) Glutarsaeurederivate und ihre herstellung.
DE60324734D1 (de) Calixaren-Derivate mit antiviraler Wirkung
EP0919233A4 (de) Therapeutisches mittel zur behandlung von nierenerkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties